Disulfidptosis: A Metabolic Cell Death Mechanism with Therapeutic Potential in Cancer

Area of Science:

• Cell Biology
• Biochemistry
• Oncology

Background:

• Regulated cell death (RCD) pathways are crucial in biology and disease.
• Understanding novel cell death mechanisms like disulfidptosis expands our knowledge of programmed cell death.
• Disulfidptosis, identified in 2023, presents a distinct modality of cell death.

Purpose of the Study:

• To review and summarize the current understanding of disulfidptosis.
• To elucidate the unique mechanisms underlying disulfidptosis.
• To explore the therapeutic potential of targeting disulfidptosis in cancer.

Main Methods:

• Review of existing literature on disulfidptosis.
• Analysis of the molecular mechanisms involving disulfide bond accumulation and redox homeostasis disruption.
• Examination of metabolic dependencies, particularly glucose deprivation and SLC7A11 expression.
• Investigation of cytoskeletal collapse as a hallmark feature.
• Summary of evidence for disulfidptosis in various tumor types.

Main Results:

• Disulfidptosis is characterized by intracellular disulfide bond accumulation and disrupted redox homeostasis.
• It is triggered by glucose deprivation in cells with high SLC7A11 expression, linked to insufficient NADPH.
• This cell death pathway leads to cytoskeletal collapse without caspase activation.
• Disulfidptosis is observed in hepatocellular carcinoma, colorectal cancer, and lung adenocarcinoma.
• Metabolic pathway modulation (e.g., GLUT1 or G6PD inhibitors) shows therapeutic potential.

Conclusions:

• Disulfidptosis is a novel, caspase-independent regulated cell death pathway.
• Its unique metabolic dependencies and mechanism offer new avenues for cancer therapy.
• Targeting disulfidptosis could exploit tumor metabolic vulnerabilities for selective cancer cell killing.